Let's break down Caplin Point Laboratories (CAPLIPOINT) — from its financial performance to how the market is valuing the stock.
Caplin Point Revenue Trend
Year-over-year, Caplin Point Laboratories grew revenue by 15.5% — from ₹1,761 Cr in FY2024 to ₹2,034 Cr in FY2025.
On a 10-year view, revenue grew from ₹252 Cr to ₹2,034 Cr at a 23.2% CAGR. That kind of compounding is what separates the growth names.
A ₹2,034 Cr revenue base makes Caplin Point Laboratories a mid-sized name in the Indian pharmaceuticals sector.
Caplin Point Laboratories has posted revenue growth for 9 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹2,034 Cr | +15.5% |
| FY2024 | ₹1,761 Cr | +15.7% |
| FY2023 | ₹1,523 Cr | +16.4% |
| FY2022 | ₹1,308 Cr | +20.6% |
| FY2021 | ₹1,085 Cr | — |
View Caplin Point Laboratories's full 10-year revenue trend with CAGR analysis →
Caplin Point Profitability
The bottom line looked healthy: Caplin Point Laboratories posted net profit of ₹541 Cr in FY2025, 17.3% above FY2024.
Margins stayed in a tight range, with net profit margin at 26.6% in FY2025.
Per-share earnings moved to ₹70.25 in FY2025 from ₹59.90 in FY2024.
Is Caplin Point Undervalued
The P/E Ratio valuation pegs Caplin Point Laboratories's fair value at ₹1,759, which is 10.8% downside from the current price.
Caplin Point Laboratories shares are currently trading at ₹1,972.90.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,759 | 10.8% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Caplin Point Laboratories with detailed assumptions →
Caplin Point Shareholding Pattern
At 70.6%, the promoter stake has been flat for the past 4 quarters.
As of March 2026, FIIs own 6.2% of the company — down from 6.2% a year earlier.
The DII stake stands at 2.1% as of March 2026, versus 2.2% in the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 70.6% | 6.2% | 2.1% | 21.1% |
| Dec 2025 | 70.6% | 6.6% | 2.0% | 20.8% |
| Sep 2025 | 70.6% | 6.5% | 2.1% | 20.8% |
| Jun 2025 | 70.6% | 6.2% | 2.2% | 21.1% |
Track quarterly shareholding changes for Caplin Point Laboratories →
Caplin Point Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹32.08B at the end of FY2025, up 18.9% from ₹26.98B a year earlier.
Other Assets is the largest block at 24.0%, followed by Property, Plant & Equipment at 20.9% and Receivables at 19.7%.
Equity makes up 90.0% of liabilities and equity, with debt at 0.2% and operating liabilities at 9.9%. Over the year, debt is up 154.8% and equity is up 23.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.11B |
| Receivables | 6.32B |
| Inventories | 3.36B |
| Property, Plant & Equipment | 6.70B |
| Investments | 2.79B |
| Intangibles & Goodwill | 112.70M |
| Other Assets | 7.69B |
| Category | Value |
|---|---|
| Equity | 28.86B |
| Short-term Debt | 21.10M |
| Long-term Debt | 29.10M |
| Trade Payables | 2.18B |
| Other Liabilities | 988.60M |
Caplin Point Stock Analysis
What should investors take away from Caplin Point Laboratories's (CAPLIPOINT) latest numbers? Here's the summary.
Revenue of ₹2,034 Cr in FY2025, up 15.5% year-over-year.
Long-term revenue has been compounding at 23.2% annually over 10 years.
The company is profitable, with a net margin of 26.6% and net income of ₹541 Cr.
The P/E Ratio model implies 10.8% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Caplin Point Laboratories's detailed profile on Craytheon.